Option chain shows key data for Sarepta Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) Stock, Option Chain

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

SLDB

SRPT



Shares of biotech company Solid Biosciences (NASDAQ:SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came out resulting in this

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

Collapsing,Dna,Molecules,On,A,Blurred,Background.

Biotech

News

Health Care

General

RHHBY

Sarepta&#39;s EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Sarepta Therapeutics&#39; Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years

biotech shutter

Analyst Color

Initiation

Analyst Ratings

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED)

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

Press Releases

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Small Cap

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Comments

Sarepta Therapeutics

Sarepta Therapeutics (SRPT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga